These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 8212915)

  • 1. A cross-sectional study on vaccine coverage and seroprevalence in schoolchildren in Andorra.
    Portella E; Goicoechea J; Penella J
    Soz Praventivmed; 1993; 38(4):245-8. PubMed ID: 8212915
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential impact on vaccination coverage levels by administering vaccines simultaneously and reducing dropout rates.
    Dietz VJ; Stevenson J; Zell ER; Cochi S; Hadler S; Eddins D
    Arch Pediatr Adolesc Med; 1994 Sep; 148(9):943-9. PubMed ID: 8075738
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunization coverage in a population-based sample of Maryland children.
    Williams IT; Dwyer DM; Hirshorn EM; Bonito RC; Graham NM
    Arch Pediatr Adolesc Med; 1994 Apr; 148(4):350-6. PubMed ID: 8148933
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Surveillance of vaccination coverage in 5-6- and 13-14-years-old schoolchildren in Geneva.
    Merle T; Jeannot E
    Arch Pediatr; 2020 Aug; 27(6):292-296. PubMed ID: 32682662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase III, open-label, randomised multicentre study to evaluate the immunogenicity and safety of a booster dose of two different reduced antigen diphtheria-tetanus-acellular pertussis-polio vaccines, when co-administered with measles-mumps-rubella vaccine in 3 and 4-year-old healthy children in the UK.
    Marlow R; Kuriyakose S; Mesaros N; Han HH; Tomlinson R; Faust SN; Snape MD; Pollard AJ; Finn A
    Vaccine; 2018 Apr; 36(17):2300-2306. PubMed ID: 29576304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody responses of healthy infants to concurrent administration of a bivalent haemophilus influenzae type b-hepatitis B vaccine with diphtheria-tetanus-pertussis, polio and measles-mumps-rubella vaccines.
    West DJ; Rabalais GP; Watson B; Keyserling HL; Matthews H; Hesley TM
    BioDrugs; 2001; 15(6):413-8. PubMed ID: 11520252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity of a low-dose diphtheria, tetanus and acellular pertussis combination vaccine with either inactivated or oral polio vaccine compared to standard-dose diphtheria, tetanus, acellular pertussis when used as a pre-school booster in UK children: A 5-year follow-up of a randomised controlled study.
    John T; Voysey M; Yu LM; McCarthy N; Baudin M; Richard P; Fiquet A; Kitchin N; Pollard AJ
    Vaccine; 2015 Aug; 33(36):4579-85. PubMed ID: 26165918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Feasible improvements in vaccines in the Expanded Programme on Immunization.
    McIntosh K
    Rev Infect Dis; 1989; 11 Suppl 3():S530-7. PubMed ID: 2669097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EPI vaccines-induced antibody prevalence in 8-9 year-olds in The Gambia.
    Viviani S; Mendy M; Jack AD; Hall AJ; Montesano R; Whittle HC
    Trop Med Int Health; 2004 Oct; 9(10):1044-9. PubMed ID: 15482396
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Vaccination coverage of school children].
    Albertos MA; Rovira G; Villalbi JR
    Rev Sanid Hig Publica (Madr); 1991; 65(3):269-75. PubMed ID: 1801187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunisation practice in developed countries.
    Hinman AR; Orenstein WA
    Lancet; 1990 Mar; 335(8691):707-10. PubMed ID: 1969069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new method for active surveillance of adverse events from diphtheria/tetanus/pertussis and measles/mumps/rubella vaccines.
    Farrington P; Pugh S; Colville A; Flower A; Nash J; Morgan-Capner P; Rush M; Miller E
    Lancet; 1995 Mar; 345(8949):567-9. PubMed ID: 7619183
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improving child survival through immunisation.
    Lamabadusuriya SP
    Ceylon Med J; 1993 Dec; 38(4):170-1. PubMed ID: 8143330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunization coverage levels among 19- to 35-month-old children in 4 diverse, medically underserved areas of the United States.
    Rosenthal J; Rodewald L; McCauley M; Berman S; Irigoyen M; Sawyer M; Yusuf H; Davis R; Kalton G
    Pediatrics; 2004 Apr; 113(4):e296-302. PubMed ID: 15060256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pertussis vaccine effectiveness among children 6 to 59 months of age in the United States, 1998-2001.
    Bisgard KM; Rhodes P; Connelly BL; Bi D; Hahn C; Patrick S; Glodé MP; Ehresmann KR;
    Pediatrics; 2005 Aug; 116(2):e285-94. PubMed ID: 16061582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Seroprevalence and vaccination coverage of vaccine-preventable diseases in perinatally HIV-1-infected patients.
    Sticchi L; Bruzzone B; Caligiuri P; Rappazzo E; Lo Casto M; De Hoffer L; Gustinetti G; Viscoli C; Di Biagio A
    Hum Vaccin Immunother; 2015; 11(1):263-9. PubMed ID: 25483544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of immune response following immunization with DTP/Td and MMR vaccines in children treated for acute lymphoblastic leukemia.
    Koochakzadeh L; Khosravi MH; Pourakbari B; Hosseinverdi S; Aghamohammadi A; Rezaei N
    Pediatr Hematol Oncol; 2014 Oct; 31(7):656-63. PubMed ID: 25007393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Are parental vaccine safety concerns associated with receipt of measles-mumps-rubella, diphtheria and tetanus toxoids with acellular pertussis, or hepatitis B vaccines by children?
    Bardenheier B; Yusuf H; Schwartz B; Gust D; Barker L; Rodewald L
    Arch Pediatr Adolesc Med; 2004 Jun; 158(6):569-75. PubMed ID: 15184221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pervasive developmental disorders in Montreal, Quebec, Canada: prevalence and links with immunizations.
    Fombonne E; Zakarian R; Bennett A; Meng L; McLean-Heywood D
    Pediatrics; 2006 Jul; 118(1):e139-50. PubMed ID: 16818529
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Persistence of antibodies in 4-8 year old Austrian children after vaccination with hexavalent DTaP-HBV-IPV/Hib and MMR vaccines.
    Paulke-Korinek M; Fischmeister G; Grac A; Rendi-Wagner P; Kundi M; Mohsenzadeh-Rabbani A; Moritz K; Fenninger B; Jarisch R; Jasinska J; Holzmann H; Wiedermann U; Kollaritsch H
    Vaccine; 2011 Jul; 29(32):5130-6. PubMed ID: 21624412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.